Le Lézard
Classified in: Health
Subjects: PDT, FDA

NGMedical GmbH Receives FDA Clearance for Its BEE® HA Cervical Cage System Made From PEEK-OPTIMATM HA Enhanced


SCOTTSDALE, Ariz., March 30, 2021 /PRNewswire/ -- NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal application, announces FDA clearance for its anatomically shaped cervical interbody BEE® HA, made of the innovative PEEK-OPTIMAtm HA Enhanced from Invibio Biomaterial Solutions, a global leader in high-performance biomaterial solutions. 

BEE® HA was developed to optimize fusion while maintaining elasticity that is similar to bone and radiolucency of the cage body. Hydroxyapatite (HA), a well-known osteoconductive material that enhances bone apposition, is fully integrated, not coated, into the PEEK-OPTIMAtm matrix, making it available on all surfaces of the finished device. This is another significant innovation from the team, who recently launched the innovative additively manufactured BEE® cage.

"This is the next step for NGMedical to broaden our active market presence in the USA. We are proud having received the FDA clearance for our new BEE® HA. Our team did a great job in cooperation with MRC Global," says Dagmar Weiland, CEO of NGMedical.

"The clearance of the BEE® HA cage is an important step to complete our portfolio with this innovative solution. This implant, along with its streamlined and elegant instrumentation, is perfectly suited for the U.S. surgeon as it addresses artifact reduced imaging while enhancing fusion," according to Josh Sandberg of NGMedical, Inc.

"More and more surgeons see PEEK-OPTIMAtm HA Enhanced solutions as their material of choice when faster, greater bone ongrowth is essential. The clinical evidence for PEEK-OPTIMAtm HA Enhanced devices demonstrates consistently good outcomes when compared to other materials, so we are excited for NGMedical to launch the BEE® HA cage in the U.S. and the potential for enhancing patient care," says John Devine, Invibio Biomaterial Solutions. 

NGMedical, Inc. is actively seeking qualified representation nationwide. If interested in learning more, please call us at (480) 609-4864. 

About NGMedical
We are an owner-managed company specializing in the development of innovative spinal implants. Many years of experience, combined with a high degree of creativity, give us the impetus to significantly advance the development of spine surgery. The NGMedical team has been developing innovative product systems since 2001. NGMedical derived out of the company Advanced Medical Technologies AG, which was acquired by Medtronic Inc. in 2012. NGMedical exploits this longtime experience combined with a high degree of creativity and know-how for the development of further innovative product concepts. Both, earlier and today, the cooperation with a team of experienced surgeons and scientists is the basis for the market-driven orientation. Many product solutions, today accepted and widely used as standards, derive from our team.

Contact
NGMedical, Inc. | Scottsdale, Arizona 

Related Images

image1.png

SOURCE NGMedical, Inc.


These press releases may also interest you

at 03:11
The eighth Aurora Prize for Awakening Humanity was awarded Thursday evening to Dr. Denis Mukwege, a world-renown gynecological surgeon and human rights activist from the Democratic Republic of the Congo (DRC). Dr. Mukwege is the president of Panzi...

at 03:05
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to...

at 03:00
Charging an electric vehicle (EV) at home is certainly more convenient than using a public charging station, but what are the other benefits? Along with convenience, the...

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:05
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and Maze Therapeutics, Inc. (Head Office: South San Francisco, California, USA; Chief Executive Officer: Jason Coloma, Ph.D.;...

at 02:00
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...



News published on and distributed by: